Breaking ground in cataract surgery: Q&A with OptiMedica CEO Mark Forchette

July 9, 2012 by Arezu Sarvestani

OptiMedica CEO Mark Forchette tells MassDevice why femtosecond laser technology is changing the game in cataract surgery and how the promise of the technology lured him away from steady path at the largest ophthalmology company.

Updated: July 18, 2012 11:30 a.m.

OptiMedica CEO Mark Forchette

OptiMedica Corp. is making waves and challenging the leaders in global eye care with its Catalys Precision Laser system for cataract surgery and CEO Mark Forchette isn't shy about extolling his company's potential.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Features

Integrity Applications looks beyond optical sensors with its GlucoTrack Model DF-F, which uses ultrasonic, electromagnetic and thermal technology to measure physiological changes associated with blood glucose levels.

Former NBA player Jonathan Bender tries his hand at entrepreneurship, aiming to bring the physical therapy device he invented to the U.S. market.

Battelle engineering manager Melissa Masters tells MassDevice.com how insights ranging from national security to aeronautics can inform the creation of disruptive new medical devices.

The special sauce in contract research organization Ora Inc.'s recipe for ophthalmology trials is the eye care practice its founder started 30 years ago.

Animal rights advocacy group PETA holds a tiny stake in several medtech companies, taking frequent advantage of its shareholder rights to push changes in the way device makers experiment on animals.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp